Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179542 | 0.83 | GAA (0.47) | CA1CA2ALDH1A1GAACA12 | |
| SCHEMBL10320491 | 0.82 | CA1 (0.56) | CA1CA2ALDH1A1GAACA12 | |
| SCHEMBL2900162 | 0.81 | EPHX2 (0.44) | CA1CA2CA12CA7CA9 | |
| SCHEMBL5546106 | 0.80 | CA1 (0.54) | CA1CA2ALDH1A1GAACA12 | |
| SCHEMBL799846 | 0.78 | ALDH1A1 (0.70) | CA1CA2ALDH1A1GAACA12 | |
| SCHEMBL17688873 | 0.78 | NQO1 (0.48) | CA1ALDH1A1CA12CA7CA9 | |
| SCHEMBL17688872 | 0.78 | GPR3 (0.44) | GAACYP1A2KDM4EMEN1MAPT | |
| SCHEMBL20249750 | 0.77 | HTT (0.43) | CA1CA2ALDH1A1GAAKDM4E | |
| SCHEMBL20746643 | 0.77 | MAOA (0.40) | CA1CA2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL9133188 | 0.77 | CA1 (0.50) | CA1CA2ALDH1A1GAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2018-07-10 | — | — | US | disclosed |
| US-9827228-B2 | Opioid receptor modulators and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-11-28 | — | — | US | disclosed |
| US-9598432-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598432-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2017039778-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | CA1 4873/4885CA2 4354/4885ALDH1A1 1105/4885 |
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | CA1 4764/4885CA2 4358/4885ALDH1A1 2315/4885 |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | CA1 4834/4885CA2 3329/4885ALDH1A1 1326/4885 |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | CA1 4873/4885CA2 4354/4885ALDH1A1 1105/4885 |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | CA1 4873/4885CA2 4354/4885ALDH1A1 1105/4885 |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP1 | CA1 740/4885CA2 1080/4885ALDH1A1 4663/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | CA1 3089/4885CA2 3037/4885ALDH1A1 3223/4885 |
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | IL2, IL1B, IL5 | CA1 4659/4885CA2 4466/4885ALDH1A1 487/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | CA1 4764/4885CA2 4358/4885ALDH1A1 2315/4885 |
| US-20170056377-A1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | OPRM1, OPRK1, OPRL1 | CA1 3969/4885CA2 4024/4885ALDH1A1 1408/4885 |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | PDE2A, PDE5A, PDE12 | CA1 4031/4885CA2 1378/4885ALDH1A1 565/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CA1 4396/4885CA2 4029/4885ALDH1A1 312/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | CA1 4870/4885CA2 4746/4885ALDH1A1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.